Cargando…
Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial
BACKGROUND: Although mass vaccination has reduced the severity of COVID-19, mortality is still high among hospitalized patients. Being a sepsis-like disease, an anti-inflammatory drug as atorvastatin would reduce mortality and severity in COVID-19. METHODS: We designed a randomized clinical trial th...
Autores principales: | Emara, Moataz Maher, Elsawy, Neamat Hamdy, Abdelaaty, Kholoud M., Elhamaky, Amal Salah, Eltahan, Naglaa Hamdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360729/ https://www.ncbi.nlm.nih.gov/pubmed/35941669 http://dx.doi.org/10.1186/s13063-022-06619-9 |
Ejemplares similares
-
Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)
por: Patel, Jaimin M, et al.
Publicado: (2012) -
Pushing the limits of PLA by exploring the power of MWCNTs in enhancing thermal, mechanical properties, and weathering resistance
por: Younus, Mohammed M., et al.
Publicado: (2023) -
A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
por: Pudi, Krishna K., et al.
Publicado: (2017) -
Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
por: Kimer, Nina, et al.
Publicado: (2020) -
Efficacy of alternate-day versus everyday dosing of atorvastatin
por: Pramanik, Sushobhan, et al.
Publicado: (2012)